In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...
Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...
The company‘s 2026 guidance and targets for 2027 and beyond should give investors a bit more cause for optimism.
Zacks Investment Research on MSN
ANIP vs. TEVA: Which drug stock is the better buy right now?
Both ANI Pharmaceuticals ANIP and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on generic and ...
A federal judge denied Teva's bid to delay the first Paragard bellwether trial, keeping a January start date for claims tied ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best performing pharma stocks in 2025. Truist lifted the ...
Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...
Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...
Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to ...
Teva Pharmaceuticals can’t delay the first trial in thousands of lawsuits over claims its Paragard intrauterine contraceptive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback